Latest news and press releases about Simulations Plus, Inc. (SLP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft.
Price
| Price | $18.43 |
| Market Cap | $373M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 44.95 |
| Price / Book | 2.67 |
| EV / EBITDA | 17.32 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -51.86% |
| Return on Invested Capital | -52.61% |
| Return on Assets | -49.05% |
| Gross Margin | 63.38% |
| Operating Margin | 14.02% |
| Net Margin | 9.88% |
Related companies: ACIU · AGL · ANRO · CLLS · DH · KRRO · NAKA
Explore sector: Technology · Software - Application
More sections of SLP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks